Fentanyl is far more potent than methadone by weight. A microgram-level dose of fentanyl produces the same pain relief as a milligram-level dose of methadone, making fentanyl roughly 50 to 100 times more potent than morphine while methadone sits in the range of 3 to 10 times morphine’s potency depending on the clinical context. But “stronger” is a slippery word when applied to opioids, and the simple potency comparison hides a more complicated reality that matters for pain treatment, overdose risk, and addiction medicine.
What Potency by Weight Actually Tells You
When pharmacologists say one opioid is “stronger” than another, they usually mean it takes fewer milligrams to produce the same effect. By that measure, fentanyl wins decisively. It is a small, highly fat-soluble molecule that crosses into the brain rapidly, which is partly why it can be delivered through skin patches and absorbed through mucous membranes at doses measured in micrograms rather than milligrams.1PubMed Central. Fentanyl Absorption, Distribution, Metabolism, and Excretion (ADME): Narrative Review and Clinical Significance Related to Illicitly-Manufactured Fentanyl But potency by weight is a pharmacological yardstick, not a clinical one. It tells you how much drug you need, not how well it works or how dangerous it is in practice. A drug that requires a tiny dose can still be matched or exceeded in clinical effect by a drug given at a larger dose.
Where things get interesting is that methadone’s potency is not fixed the way fentanyl’s is. A critical review of equianalgesic dosing found that methadone is “more potent than previously appreciated” and that the conversion ratio between methadone and other opioids shifts depending on how much opioid the patient was already taking.2Journal of Pain and Symptom Management. Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing Someone on a high dose of another opioid who switches to methadone needs proportionally less methadone than the standard conversion charts would predict. This sliding-scale behavior is unusual among opioids and makes methadone harder to dose but also, in certain situations, surprisingly effective at doses that look modest on paper.
Methadone’s Unusual Pharmacology
Fentanyl is essentially a one-trick molecule. It binds powerfully to the mu-opioid receptor, and that binding drives virtually all of its effects: pain relief, euphoria, respiratory depression. Lab studies show fentanyl activates the cell-signaling pathway downstream of the mu receptor with high efficacy, meaning it squeezes a strong biological response out of the receptor once it binds.3PubMed Central. In vitro functional profiling of fentanyl and nitazene analogs at the μ-opioid receptor reveals high efficacy for Gi protein signaling
Methadone does something different. It acts on the mu-opioid receptor, but it also blocks a completely separate receptor called the NMDA receptor. The NMDA receptor plays a role in how the nervous system amplifies and sustains pain signals, particularly in neuropathic pain, the burning or shooting type caused by nerve damage. By blocking NMDA receptors at concentrations much lower than what morphine would require, methadone addresses a pain pathway that most opioids largely ignore.4PubMed. Opioid Add-On Combination Therapy for Cancer Pain: Pharmacological Rationale, Clinical Evidence, and Future Directions On top of that, one of methadone’s two mirror-image molecular forms inhibits the reuptake of serotonin and norepinephrine, a mechanism shared with certain antidepressants that are themselves used for chronic pain.5PubMed Central. Methadone for Chronic Pain: A Review of Pharmacology, Efficacy, and Safety Concerns
This means methadone is doing three things at once where fentanyl is doing one. In clinical settings where pain has a neuropathic component, methadone can outperform fentanyl not because it is “stronger” at the opioid receptor but because it is working additional channels that fentanyl cannot reach.
Why Switching Between Them Is So Difficult
Standard opioid conversion tables treat the relationship between drugs as roughly fixed: X milligrams of drug A equals Y milligrams of drug B. For most opioid pairs, this works well enough. For methadone, it breaks down. The review that flagged methadone’s unexpected potency also found that the conversion ratios show “extremely wide ranges” and that the ratio changes depending on which direction the switch goes, from methadone to another opioid or the other way around.2Journal of Pain and Symptom Management. Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing
A key reason for this is incomplete cross-tolerance. When someone has been taking one opioid for a long time and switches to another, the tolerance they built to the first drug does not fully transfer to the second. Clinical evidence from cancer patients who had stopped responding to high doses of other opioids showed that switching to methadone restored pain control at doses that were modest compared to what the patient had been taking before. The amount of methadone needed was far less than standard conversion tables would have predicted.6Cancer. Clinical efficacy of methadone in patients refractory to other μ-opioid receptor agonist analgesics for management of terminal cancer pain This incomplete cross-tolerance is clinically useful, allowing methadone to “reset” pain relief in patients whose previous opioid had stopped working. But it is also dangerous: if a clinician calculates the methadone dose using a standard table without accounting for this effect, the patient can receive too much.
Fentanyl adds its own conversion wrinkle. The same critical review noted that discrepancies exist specifically for fentanyl in equianalgesic tables, meaning that published ratios for fentanyl-to-other-opioid conversions may not be reliable either.2Journal of Pain and Symptom Management. Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing When you are converting between two drugs that both have unreliable conversion ratios, the margin for error compounds. This is why switching from fentanyl to methadone or vice versa typically requires careful dose titration by an experienced clinician rather than a simple calculation.
How They Compare for Pain Relief
Head-to-head clinical studies of methadone and fentanyl in pain management are uncommon, but the ones that exist tell a consistent story: the two drugs are broadly comparable for general cancer pain, with methadone showing an edge in specific situations. A trial comparing sustained-release morphine, transdermal fentanyl, and oral methadone as first-line treatment for cancer pain found that all three were effective and well tolerated, with similar needs for additional painkillers. Methadone was significantly cheaper, though it required more frequent dose adjustments, underscoring that it demands more clinical expertise to manage.7European Journal of Pain. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management
Where methadone pulled ahead was neuropathic pain. A study of head-and-neck cancer patients with nerve-related pain found that methadone reduced pain scores more than fentanyl at every time point measured, with a significantly higher rate of clinical success (defined as more than 50 percent improvement) at one week.8European Journal of Cancer. Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer This advantage aligns with methadone’s NMDA-blocking mechanism described earlier. Fentanyl, lacking that secondary action, has less to offer when the pain has a nerve-damage component.
When cancer patients on fentanyl patches were switched to oral methadone, the rotation was fully or partially effective for somatic pain in all patients studied. Symptoms like delirium and involuntary muscle jerking, which had developed on fentanyl, resolved after the switch.9PubMed. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain This suggests that for some patients, fentanyl’s side effects become the limiting factor rather than its analgesic ceiling, and methadone offers a way around that wall.
Different Overdose Risks
Both drugs can kill. But they threaten life through partly different mechanisms, and the timing of danger differs sharply.
Fentanyl’s primary overdose danger is rapid, profound respiratory depression. A narrative review of opioid-induced respiratory depression concluded that fentanyl carries the greatest risk of causing both respiratory depression and reduced blood flow to the brain among commonly used opioids. Because fentanyl is so lipophilic and reaches the brain so quickly, there is very little lag between exposure and the onset of breathing problems. Additionally, fentanyl can trigger a phenomenon sometimes called “wooden chest syndrome,” in which the muscles of the chest wall and abdomen become rigid, making it physically impossible for the person to breathe even if the brain is still sending the signal to do so.10PubMed Central. Wooden Chest Syndrome: A Case Report of Fentanyl-Induced Chest Wall Rigidity This complication, known primarily in hospital anesthesia settings, has become increasingly relevant in street overdoses involving illicitly manufactured fentanyl.
Methadone’s overdose risk is more insidious. Its elimination half-life is exceptionally long, sometimes exceeding 24 hours and in some individuals stretching well past that. This means the drug accumulates over days rather than peaking and fading within hours the way fentanyl does. A person can feel fine on a given dose for the first day or two, only to develop dangerous respiratory depression on day three as the drug builds up in their system. Methadone also carries a cardiac risk that fentanyl does not: it can prolong the QT interval on an electrocardiogram, which in turn raises the risk of a potentially fatal heart rhythm called torsades de pointes.11PubMed Central. Methadone, QTc prolongation and torsades de pointes: Current concepts, management and a hidden twist in the tale?
Reversing either overdose with naloxone presents challenges. Naloxone itself is short-acting, with a duration of effect that is shorter than that of many opioid agonists. For fentanyl, the concern is that the initial naloxone dose may not fully overcome fentanyl’s strong receptor binding, requiring repeated doses. For methadone, the problem is the other way around: naloxone may reverse the overdose initially, but because methadone lingers so long in the body, the patient can slip back into respiratory depression after the naloxone wears off, a phenomenon called re-narcotization. This risk is well documented for any long-acting opioid.12PubMed Central. Naloxone dosage for opioid reversal: current evidence and clinical implications
Methadone as Treatment in the Fentanyl Era
One of the most practically important comparisons between these two drugs is not which is stronger but whether methadone, used as a treatment for opioid use disorder, still works when the drug a person is addicted to is fentanyl rather than heroin. Illicitly manufactured fentanyl has largely replaced heroin in much of the drug supply, and early concerns suggested that fentanyl’s extreme potency might make methadone maintenance less effective or require much higher doses.
The clinical evidence so far is reassuring. A year-long study at a methadone clinic in an area where fentanyl dominated the illicit supply found that patients who tested positive for fentanyl at intake did about as well as those who did not. Roughly half of each group remained in treatment for the full 12 months, and among those who stayed, about three-quarters achieved remission, defined as consecutive clean urine screens. The median dose needed to reach remission was the same in both groups, around 100 milligrams per day, and the time to remission was nearly identical.13PubMed Central. One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission
What has changed is how quickly clinicians are willing to raise the dose at the start of treatment. Traditional methadone induction protocols increased the dose slowly over weeks, a pace designed to avoid the accumulation risk described above. But patients using fentanyl often have very high opioid tolerance and experience severe withdrawal on the low starting doses of older protocols. Several clinics have adopted rapid induction schedules that bring the dose to 80 milligrams or more within the first week. A case series from one outpatient program using a protocol of 40 milligrams on day one, 60 on day two, and 80 on day three reported no episodes of oversedation or overdose, and 85 percent of patients were still in treatment at 30 days.14PubMed Central. Induction to Methadone 80 mg in the First Week of Treatment of Patients Who Use Fentanyl: A Case Series From an Outpatient Opioid Treatment Program A systematic review of rapid inpatient induction protocols found that starting doses of 30 to 40 milligrams with daily or symptom-triggered increases could achieve 60 to 100 milligrams within five to seven days, substantially faster than older outpatient schedules.15Current Addiction Reports. Rapid Inpatient Methadone Induction in the Fentanyl Era: A Systematic Review of Safety, Efficacy, and Protocols for Hospitalized Patients with Opioid Use Disorder
The shift toward faster induction reflects an understanding that undertreating fentanyl-tolerant patients in the first days of treatment drives them back to street drugs. A dose that might have been dangerous for a heroin user can be safe for someone whose tolerance has been set by daily fentanyl exposure.
How Speed of Onset Shapes Each Drug’s Profile
Beyond raw potency and receptor binding, the speed at which each drug reaches the brain shapes nearly everything about how it is experienced and misused. Fentanyl reaches equilibrium with brain tissue in about six minutes; methadone is only slightly behind at roughly eight minutes.16Journal of Pain and Symptom Management. Pharmacokinetic–Pharmacodynamic Modeling of Opioids Those equilibration times sound similar, but the broader pharmacokinetic picture diverges enormously. Fentanyl’s clinical effect after a single intravenous dose fades within about an hour as the drug redistributes out of the brain and into muscle and fat. Methadone, by contrast, stays active for many hours because it is released back into the bloodstream slowly from tissue stores.
This difference in duration is why fentanyl dominates the illicit market as a drug of abuse and why methadone dominates as a treatment drug. Fentanyl delivers a fast, intense rush that wears off quickly, driving repeated dosing. Methadone provides steady opioid-receptor occupancy that suppresses withdrawal and cravings without the dramatic peaks and valleys. Neither property has anything to do with which drug is “stronger” in an absolute sense. It is about the shape of the drug’s effect over time, not its height.
Genetic Variation in Methadone Metabolism
One reason methadone’s clinical behavior is so unpredictable compared to fentanyl is that your genes have an outsized influence on how quickly your body breaks it down. Methadone is metabolized by several liver enzymes, and common genetic variations in the genes coding for those enzymes can cause dramatic differences in how much active drug ends up in the bloodstream. Variations in genes like CYP2B6, CYP3A4, CYP2C19, CYP2D6, and CYP3A5 have all been linked to increased methadone blood levels, slower breakdown, and reduced clearance.17Biochemical Pharmacology. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics
In practical terms, two people taking the same dose of methadone can end up with very different amounts of active drug in their blood. One person may metabolize it briskly and need a higher dose, while another may be a slow metabolizer who accumulates the drug to dangerous levels on a standard dose. This variability is one reason methadone-related overdose deaths can happen even at prescribed doses, and it is a major reason that methadone dose changes must be made slowly and with careful monitoring. Fentanyl is also metabolized by liver enzymes, but the clinical impact of genetic variation on fentanyl dosing is generally smaller and less studied in this context, in part because fentanyl’s shorter duration of action gives less time for accumulation to become dangerous.
For patients and families trying to understand these drugs, the bottom line on genetic variability is that the “right” dose of methadone varies enormously from person to person in a way that fentanyl dosing does not. This is another dimension in which the question of which drug is stronger resists a simple answer. For a slow metabolizer, a standard methadone dose could act as if it were a much stronger drug than intended.